Return to search

ReViral snags $44m Series C

ReViral Ltd., a clinical-stage biopharmaceutical company, has raised $44 million in Series C financing.

ReViral Ltd., a clinical-stage biopharmaceutical company, has raised $44 million in Series C financing. CR-CP Life Science Fund led the round with participation from other investors that included Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors and Perceptive Advisors.

Source: Press Release